Myllykangas-luosuj？rvi R, Aho K, Kautiainten H, et al. Shortening of life span and causes of excess mortality in a populationbasedseries of subjects with rheumatoid arthritis[J]. Clin Exp Rheumatol, 1995, 13(2): 149-153.
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum, 1988, 31(3): 315-324.
Salonen R, Nyyssonen K, Porkkla E, et al. Kuopio Atherosclerosis Prevention Study(KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and fermoral arteries[J].Circulation, 1995, 92(7): 1758-1764.
[6]
Sattar N, McCarey DW, Capell H, et al. Explaining how "high grade" systemin infla-mmation accelerates vascular risk in rheumatoidarthritis[J]. Circulation, 2003, 108(24): 2957-2963.
[7]
Panoulasl VF, Milionis HJ, Douglas KM, et al. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis[J]. Rheumatology, 2007, 46(9): 1466-1470.
[8]
van Halm VP, Nielen MM, Nurmohamed MT, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis[J]. Ann Rheum Dis, 2007, 66(2): 184-188.
[9]
Walldius G, Jungner I. The apoB/apoA-I ratio: a strong new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence[J]. J Intern Med, 2006, 259(5): 493-519.
[10]
Luc G, Bard JM, Ferrières J, et al. Value of HDL cholesterol apolipoprotein A-I lipoprotein A-I and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study Prospective Epidemiological Study of Myocardial Infarction[J]. Arterioscler Thromb Vasc Biol, 2002, 22(7): 1155-1161.
[11]
Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study[J]. Lancet, 2001, 358(9298): 2026-2033.
[12]
Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels,triglycerides, lipoprotein(a),apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study[J]. Circulation, 2001, 104(10): 1108-1113.
[13]
Sharett AR, Patsch VV, Sorlie PD, et al. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study[J]. Arterioscler Thromb, 1994, 14 (7): 1098-1104.
[14]
Steer P, Millg？rd J, Sarabi DM, et al. Cardiac and vascular structure and function are related to lipid peroxidation and metabolism [J]. Lipids, 2002, 37(3): 231-236.
[15]
Keulen ET, Kruijshoop M, Schaper NC, et al. Increased intima-media thickness in familia combined hyperlipidemia associated with apolipoprotein B[J]. Arterioscler Thromb Vasc Biol, 2002, 22(2): 283-288.
